Rik J. Scheper

33.6k citations

391 papers · 26.6k indexed · 9 hit papers · h-index 86

Impact in

Oncology top 0.05%
- Drug Transport and Resistance Mechanisms
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Immunology top 0.1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology

Papers in

Immunology 198
- Immunotherapy and Immune Responses 125
- T-cell and B-cell Immunology 91
- Immune Cell Function and Interaction 79
Oncology 183
- Drug Transport and Resistance Mechanisms 107
- CAR-T cell therapy research 36

Co-authors: George L. Scheffer Tanja D. de Gruijl Herbert M. Pinedo Susan Gibbs Alfons J.M. van den Eertwegh Piet Borst B. Mary E. von Blomberg Marcel de Haas
Journals: International Journal of Cancer (20 papers)The Journal of Immunology (18 papers)Cancer Immunology Immunotherapy (16 papers)Blood (15 papers)Journal of Investigative Dermatology (13 papers)
Partner nations: Netherlands United States Germany

In The Last Decade

Rik J. Scheper

390 papers receiving 25.9k citations

Hit Papers

9 papers align trajectories log scale

The Keloid Disorder: Heterogeneity, Histopathology, Mechanisms and Models 2020 · 214 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Frontiers in Cell and Developmental Biology
2002 Proceedings of the National Academy of Sciences
1999 Proceedings of the National Academy of Sciences
1997 PubMed
1996 Science
1995 Nature Medicine
1994 Proceedings of the National Academy of Sciences
1994 Proceedings of the National Academy of Sciences
1989 Journal of Clinical Oncology

Peers

Countries citing papers authored by Rik J. Scheper

Since Specialization

Citations

This map shows the geographic impact of Rik J. Scheper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rik J. Scheper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rik J. Scheper more than expected).

Fields of papers citing papers by Rik J. Scheper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rik J. Scheper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rik J. Scheper. The network helps show where Rik J. Scheper may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Rik J. Scheper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rik J. Scheper Line = papers co-authored together Rik J. Scheper links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I–II Melanoma: Data from Two Randomized Phase II Trials Clinical Cancer Research ·Bas D. Koster, Mari F.C.M. van den Hout, Berbel J.R. Sluijter, Barbara G. Molenkamp, Ronald J.C.L.M. Vuylsteke, Arnold Baars, Paul A.M. van Leeuwen, Rik J. Scheper, M. Petrousjka van den Tol, Alfons J.M. van den Eertwegh, Tanja D. de Gruijl	2017	54
2	Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence Cancer Immunology Research ·Mari F.C.M. van den Hout, Bas D. Koster, Berbel J.R. Sluijter, Barbara G. Molenkamp, Rieneke van de Ven, Alfons J.M. van den Eertwegh, Rik J. Scheper, Paul A.M. van Leeuwen, M. Petrousjka van den Tol, Tanja D. de Gruijl	2017	37
3	Increased epidermal thickness and abnormal epidermal differentiation in keloid scars British Journal of Dermatology ·Grace C. Limandjaja, Chun Wang Chau, Taco Waaijman, Anthony Sudekum, Vincent Everts, Stan Monstrey, Rik J. Scheper, Frank B. Niessen, Susan Gibbs	2016	80
4	Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141+ Dendritic Cells and Enhanced Cross-Presentation Cancer Immunology Research ·Berbel J.R. Sluijter, Mari F.C.M. van den Hout, Bas D. Koster, Paul A.M. van Leeuwen, Famke L. Schneiders, Rieneke van de Ven, Barbara G. Molenkamp, Saskia Vosslamber, Cornelis L. Verweij, M. Petrousjka van den Tol, Alfons J.M. van den Eertwegh, Rik J. Scheper, Tanja D. de Gruijl	2015	50
5	Folates and antifolates in rheumatoid arthritis Pteridines ·Gerrit Jansen, Karin Weijers, PR Pujado, Favour A. Obu, Yoony Y. J. Gent, Doralbis Alfaro, Kailiang Qi, Carla F.M. Molthoff, Cor L. Verweij, 祐一稲田, Willem F. Lems, Rik J. Scheper, Godefridus J. Peters, Manohar Ratnam, Barbara Jo Lantz, Ben A. C. Dijkmans	2013	1
6	Potent Antitumor Immunity Generated by a CD40-Targeted Adenoviral Vaccine Cancer Research ·Basav N. Hangalapura, Dinja Oosterhoff, Jan de Groot, Louis Boon, Thomas Tüting, Alfons J. van den Eertwegh, Winald R. Gerritsen, Victor W. van Beusechem, Alexander Pereboev, David T. Curiel, Rik J. Scheper, Tanja D. de Gruijl	2011	26
7	Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival Clinical Cancer Research ·Hester van Cruijsen, Astrid A.M. van der Veldt, Brenda O’Driscoll, Dinja Oosterhoff, Henk J. Broxterman, Rik J. Scheper, Giuseppe Giaccone, John B.A.G. Haanen, Alfons J.M. van den Eertwegh, Epie Boven, Klaas Hoekman, Tanja D. de Gruijl	2008	111
8	In vitro priming of tumor-specific cytotoxic T lymphocytes from healthy donors using allogeneic dendritic cells derived from the MUTZ-3 cell line (NMDC) Cancer Research ·Saskia J. Santegoets, Marco W.J. Schreurs, Allan J. Masterson, Hans Baumeister, Steffen Goletz, Esther W. M. Kueter, Sinéad M. Lougheed, E.-H. Kim, Rik J. Scheper, Erik Hooijberg, Tanja D. de Gruijl	2004	1
9	Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. PubMed ·Marieke H. Mossink, Arend van Zon, Gary D. Thurber, Martijn Schoester, Valerie A. Kickhoefer, George L. Scheffer, Rik J. Scheper, Pieter Sonneveld, Erik A.C. Wiemer	2002	75
10	Peptide transport by the multidrug resistance protein MRP1. PubMed ·Mariska C. de Jong, Jerry W. Slootstra, George L. Scheffer, Anouk B. Schroeijers, Wouter C. Puijk, Armelle Dalomis, Marcel Kool, HJ Broxterman, Rob H. Meloen, Rik J. Scheper	2001	49
11	The Multidrug Resistance Protein 1: A Functionally Important Activation Marker for Murine Th1 Cells The Journal of Immunology ·Stefan Prechtl, Le Ba Hong, Rik J. Scheper, Susan P.C. Cole, Roger G. Deeley, Michael Lohoff	2000	32
12	P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias. PubMed ·Daniela Damiani, Mariagrazia Michieli, Anna Ermacora, Anna Candoni, Donatella Raspadori, Antonella Geromin, Raffaella Stocchi, Jayleene West, Paola Masolini, Angela Michelutti, Rik J. Scheper, Michele Baccarani	1998	30
13	Vaults Are Up-regulated in Multidrug-resistant Cancer Cell Lines Journal of Biological Chemistry ·Valerie A. Kickhoefer, 一法富永, George L. Scheffer, William S. Dalton, Rik J. Scheper, Leonard H. Rome	1998	207
14	Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines International Journal of Cancer ·Carolyn M. Laurençot, George L. Scheffer, Rik J. Scheper, Robert H. Shoemaker	1997	61
15	Expression of the human major vault protein LRP in acute myeloid leukemia. PubMed ·Stephen M. Hart, K. Ganeshaguru, Rik J. Scheper, 賢一西沢, A. Victor Hoffbrand, A. Mehta	1997	38
16	Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. PubMed ·Marcel Kool, Marcel de Haas, George L. Scheffer, Rik J. Scheper, Ema S. Dreseris, Jenneke A. Juijn, Frank Baas, Byung-Jin CH이 Hit paper breakdown →	1997	746
17	Tissue distribution of the multidrug resistance protein. PubMed ·M J Flens, G J Zaman, Paul van der Valk, Miguel Izquierdo, Anouk B. Schroeijers, George L. Scheffer, Mayly Pastora, Marcel de Haas, Coby Meijer, Rik J. Scheper	1996	406
18	A Monoclonal Antibody against Human β-Glucuronidase for Application in Antibody-Directed Enzyme Prodrug Therapy PubMed ·Hidde J. Haisma, Simone Wills, George L. Scheffer, Rik J. Scheper, Herbert M. Pinedo, Epie Boven	1995	10
19	Membrane transport proteins associated with drug resistance expressed in human melanoma. PubMed ·Dirk Schadendorf, Yiming Wang, Γεώργιος Δεδεγκίκας, George S. Athwal, F. Mannucci, G L Scheffer, M J Flens, Rik J. Scheper, О. Г. Гапонова	1995	72
20	Hapten-cell conjugates in DNCB contact sensitivity. In vitro stimulation with DNP-conjugates optimally inducing contact sensitivity in vivo. PubMed ·K. Sokolowski, Rik J. Scheper	1980	3

About Rik J. Scheper

Rik J. Scheper is a scholar working on Immunology, Oncology, Dermatology, Immunology and Allergy and Rehabilitation, having authored 391 papers that have together received 26.6k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (125 papers), Drug Transport and Resistance Mechanisms (107 papers), T-cell and B-cell Immunology (91 papers), Immune Cell Function and Interaction (79 papers), Contact Dermatitis and Allergies (40 papers), CAR-T cell therapy research (36 papers), Pharmacological Effects and Toxicity Studies (34 papers) and Monoclonal and Polyclonal Antibodies Research (24 papers). The work is most often cited by research in Oncology (13.9k citations), Immunology (7.4k citations), Dermatology (2.3k citations), Pediatrics, Perinatology and Child Health (3.9k citations) and Immunology and Allergy (1.0k citations). Rik J. Scheper has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include George L. Scheffer, Tanja D. de Gruijl, Herbert M. Pinedo, Susan Gibbs, Alfons J.M. van den Eertwegh, Piet Borst, B. Mary E. von Blomberg, Marcel de Haas, Frank Baas and Marcel Kool. Their work appears in journals such as International Journal of Cancer, The Journal of Immunology, Cancer Immunology Immunotherapy, Blood and Journal of Investigative Dermatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact